Clinical trial
Xcellerated T CellsTM in Patients With Multiple Myeloma
NCT00078065 · Xcyte Therapies, Industry · Completed
Key facts
| NCT number | NCT00078065 |
|---|---|
| Title | Xcellerated T CellsTM in Patients With Multiple Myeloma |
| Official title | A Randomized Phase II Study of Xcellerated T CellsTM With or Without Prior Fludarabine Therapy in Patients With Multiple Myeloma |
| Lead sponsor | Xcyte Therapies, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Xcellerated T Cells |
| Enrollment | 30 |
| Start date | Nov 1, 2003 |
| Completion | Jun 1, 2004 |
| First posted | Feb 20, 2004 |
| Last update posted | Nov 11, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: